Aikium Inc. develops SeqR proteins, a proprietary non-antibody scaffold designed to bind to intrinsically disordered regions of proteins, specifically targeting GPCRs in oncology, auto-immune diseases, and neuro-inflammatory disorders. Their technology enables the production of nanomolar binders for challenging targets where traditional antibody and small molecule approaches have failed.
Funding
$1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many therapeutic targets, particularly GPCRs, possess intrinsically disordered regions that are difficult to address with traditional antibody or small molecule approaches. This limitation hinders the development of effective treatments for oncology, autoimmune diseases, and neuro-inflammatory disorders.
Solution
Aikium Inc. is developing SeqR proteins, a novel non-antibody scaffold engineered to bind to intrinsically disordered regions of proteins, specifically GPCRs. Enabled by AI and synthetic biology, the SeqR platform generates high-affinity binders for challenging targets where conventional methods have proven inadequate. The company's Yotta-ML² platform leverages trillion-protein mRNA display and patented generative AI based on protein language models to accelerate the discovery and optimization of SeqR proteins. This approach allows for the creation of nanomolar binders to disordered epitopes across a wide range of targets.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions seeking novel biologics for challenging therapeutic targets, particularly GPCRs with intrinsically disordered regions.
Features
- Proprietary SeqR scaffold derived from a privileged human protein
- Yotta-ML² platform for large-scale machine learning on SeqR libraries
- Trillion-protein mRNA display for generating diverse SeqR candidates
- Patented generative AI based on protein language models for SeqR design
- Capability to produce nanomolar binders to disordered epitopes
- Targeting GPCRs in oncology, autoimmune diseases, and neuro-inflammatory disorders